Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries through its novel discovery engine for lncRNAs and clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo's discovery engine, FLAME™ (Flamingo LncRNA Antisense Mining Engine), is a premier platform for lncRNAs, a large and untapped class of disease-causing targets within the "dark matter" of the human genome. Flamingo has a discovery alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV. The company is headquartered in Belgium with additional operations in San Diego, CA.
